invIOs is advancing a focused PIPELINE OF PROGRAMS spanning cell-therapy and small-molecule approaches. We specialize in early stage development, progressing assets from discovery through preclinical into clinical development.
APN401
APN401 is the first program on our EPiC cell-therapy platform, ready for phase 2 to evaluate clinical efficacy in patients with a wide range of solid tumors.
This autologous cell therapy leverages our rapid cell-processing technology to manufacture a product derived from peripheral blood mononuclear cells (PBMCs). Using a transient small interfering RNA (siRNA) approach, the intracellular immune checkpoint Cbl-b is silenced in PBMCs.
APN401 is administered in multiple treatment cycles, each utilizing freshly isolated PBMCs. It is designed to amplify the pool of functional immune cells, and overcome adaptive resistance mechanisms within the tumor microenvironment.
In 2025 we successfully completed Phase 1 trial, demonstrating the technical and clinical feasibility of integrating our EPiC platform into routine clinical workflows.
This study further confirmed that both single and multiple infusions of APN401 are well tolerated, with no serious adverse events observed.
INV441
INV441 is the lead program on our EPiC cell therapy platform, currently in development for the treatment of glioblastoma, an aggressive and deadly brain tumor representing one of the most urgent unmet needs in oncology.
INV441 utilizes our rapid cell-processing technology to transiently modify tumor-infiltrating lymphocytes (TILs) via small interfering RNA (siRNA)-mediated silencing of Cbl-b, an intracellular checkpoint that negatively regulates T-cell activation. By blocking Cbl-b, TILs gain enhanced resistance to the immunosuppressive cues of the tumor microenvironment (TME), leading to robust antitumor immunity and increased cytotoxic activity against glioblastoma cells.
Following successful completion of preclinical studies, INV441 is now advancing into a first-in-human clinical trial at the Dana-Farber Cancer Institute in Boston, USA.
INV451
INV451 is an early-stage preclinical program on our EPiC cell therapy platform, focused on the development of transient CAR PBMCs for the treatment of various solid tumors.
This program leverages our rapid cell-processing technology to transiently modify immune cells by introducing mRNA encoding a chimeric antigen receptor (CAR). The co-delivery of siRNA targeting Cbl-b enhances the cells’ resistance to the immunosuppressive signals present in the TME, resulting in a stronger antitumor response and increased cytotoxicity against tumors expressing the undisclosed CAR-antigen.
INV461
INV461 is an early-stage program on our EPiC cell therapy platform, focused on the development of tri-specific CAR T-cells for hematologic malignancies, with an initial emphasis on acute myeloid leukemia (AML).
This program leverages our rapid cell-processing technology to transiently modified T cells with three mRNA-encoded chimeric antigen receptors (CARs), enabling simultaneous targeting of leukemia-associated antigens. By addressing antigen heterogeneity and reducing the risk of antigen escape, INV461 is designed to enhance anti-leukemic efficacy while maintaining a favorable safety profile through transient CAR expression. The EPiC platform further enables fast, flexible, and repeatable dosing, supporting clinical use in time-sensitive settings such as bridge-to-transplant therapy.
INV501
INV501 is an orally available small molecule for immune activation aimed at targeting tumors with low immunogenicity.
The clinical candidate A2-1009 is currently undergoing IND-enabling studies.
A2-1009 emerged as the lead clinical candidate through a screening process designed to identify compounds capable of enhancing T-cell activity in an antigen-specific way.
As a member of a novel class of substances, A2-1009 demonstrates significant in vivo tumor growth control across multiple solid tumor models and a favorable pharmacokinetic and safety profile.
